Skip to main content

Table 1 miRNAs expression level, their targets, functional roles and potentials as biomarker in human breast cancer (female)

From: The roles of miRNAs in human breast cancer and canine mammary tumor

miRNA Human (Female) Sample Source Expression Level Target Functional Role, Biomarker as Diagnostic, Prognostic, Therapeutic Authors, year of publication
Let 7 family Cell line, Tissue, Blood, Serum Down RAS, HMGA2, H-RAS, KRAS, MYC, CCND2, PBX3, LIN28, PEBP1, BMI-1 Proliferation, differentiation, self-renewal, EMT, Tamoxifen response, diagnostic and prognostic biomarker Kurozumi et al. 2016 [57], Bertoli et al. 2015 [3]
Schooneveld et al. 2015 [36], Kaboli et al. 2015 [58], Takahashi et al. 2015 [59], Zhang et al. 2014 [60], Schwarzenbacher et al. 2013 [61], Fu et al. 2011 [62], O′ Day et al. 2010 [2]
7 Tissue Down FAK, IGFR, EGFR, REGγ Regulating gene expression, cell growth and survival control, Tamoxifen response, Docetaxel and Cisplatin sensitive, diagnostic biomarker Bertoli et al., 2015 [3], Kaboli et al. 2015 [58]
9 ER+ tissue, Cell line Up CCND1, E-CAD, CDH1 Regulate CDKs and control cell cycle progression G1 to S, cellular adhesion and metastasis, diagnostic and prognostic biomarker Bertoli et al., 2015 [3], Kaboli et al. 2015 [58],
Schooneveld et al. 2015 [36], Zhang et al. 2014 [60]
10b Cell line, Tissue Up HOXD 10, SYNDECAN-1, TIAM1, E-CAD, RHOC Promote cell migration, invasion, metastasis, EMT, stemness of BCSC,
Tamoxifen resistance, diagnostic biomarker
Bertoli et al. 2015 [3], Schooneveld et al. 2015 [36]
Kaboli et al. 2015 [58], Takahashi et al. 2015 [59],
Shafi et al. 2014 [32], Zhang et al. 2014 [60], Fu et al. 2011 [62], O′ Day et al. 2010 [2]
16 Plasma, Tissue, Cell line, Serum Down WIP1, BCL2, E2F, CDK6, CCND1 Regulate cell proliferation and death, diagnostic and prognostic, Doxorubicin and Docetaxel response Bertoli et al. 2015 [3], Kaboli et al. 2015 [58],
Zhang et al. 2014 [60], Schwarzenbacher et al. 2013 [61],
17-5p Tissue Down E2F1, CCND1, AIB1 Regulate CDKs and control cell cycle progression G1 to S, cancer cell proliferation, diagnostic biomarker Kurozumi et al. 2016 [57], Bertoli et al. 2015 [3],
Fu et al. 2011 [62], O′ Day et al. 2010 [2]
17/92 Cell line Up E2Fs, ERα, C-MYC, AIB1, CYCLIN D1, MEKK2 Control cell cycle, proliferation, tumorigenesis, proapoptosis, metastasis Kaboli et al. 2015 [58], Schooneveld et al. 2015 [36], Xiang et al. 2010 [63], Bonauer et al. 2009 [64]
21 Plasma/Tissue/Cell line, Serum, Blood Up PTEN, BCL-2, TPM1, TIMP3, HER, PDCD4, MASPIN, CDC25, PTEN, BCL2, RHOB, MMPs, HIF1A Promote cell migration, invasion, metastasis, EMT, diagnostic and prognostic biomarkers, resistant to Cisplatin, Doxorubicin, Topotecan Kurozumi et al. 2016 [57], Bertoli et al. 2015 [3],
Schoonevel et al. 2015 [36], Kodahl et al.2014 [65], Shafi et al. 2014 [32], Zhang et al. 2014 [60]
22 Cell line Down CDK6. SIRT1, SP1, TET1–3, TIP60 Regulator of cellular senescence, inhibit tumor growth and metastasis, regulate EMT genes by repressing TIP60, prognostic biomarker (TIP60/miR-22) Kaboli et al. 2015 [58], Takahashi et al. 2015 [59], Schwarzenbacher et al. 2013 [61]
27a Tissue Up FOXO1, ZBTB10/RINZF, MYT-1, ZBTB10 Cell cycle progression G2 to M check point regulation, tumor development, invasion and metastasis, diagnostic and prognostic biomarker Kurozumi et al. 2016 [57], Bertoli et al. 2015 [3], Zhang et al. 2014 [60], Tang et al. 2012 [66], Fu et al. 2011 [62], Mertens-Talcott et al. 2007 [67]
27b TNBC, Cell line and tissue Up CYP1B1, ARFGEF1, FOXO1, PPARγ, ST14, NISCH Regulate cell cycle progression, proliferation, metastasis, angiogenesis, drug resistance, generation of breast cancer stem cells (BCSCs), prognostic biomarker Ding et al. 2017 [68], Kurozumi et al. 2016 [57], Bertoli et al. 2015 [3], Zhang et al. 2014 [60], Schoonevel et al. 2015 [36], Fu et al. 2011 [62]
29b Tissue Down ITGB1, MMP2, TIAM1, VEGFA, ANGPTL4, LOX Inhibit proliferation, angiogenesis and metastasis. Diagnostic biomarker Kurozumi et al. 2016 [57], Bertoli et al. 2015 [3]
30 TNBC, Cell line and BCSCs Down UBC9, ITGB3, AVEN Regulate self-renewal and antiapoptotic, in-vitro mammosphere formation. Bertoli et al. 2015 [3], Kaboli et al. 2015 [58]
Schwarzenbacher et al. 2013 [61]
30c Tissue Down TWF1, IL-11, VIM Tamoxifen response, suppresses interleukin 11 expression and inhibit resistance to paclitaxel and doxorubicin Kurozumi et al. 2016 [57], Bertoli et al. 2015 [3],
Takahashi et al. 2015 [59]
31 BC and TNBC cell line Down RHOA, RDX, ITGA5, FZD3, M-RIP, MMP16, WAVE3, PKCepilon Inhibits several steps of the invasion-metastasis cascade in breast cancer Kurozumi et al. 2016 [57], Bertoli et al. 2015 [3],
Kaboli et al. 2015 [58], Schooneveld et al. 2015 [36],
Zhang et al. 2014 [60], Fu et al. 2011 [62], O′ Day et al. 2010 [2]
34a, b, c BC and TNBC cell line,
Tissue
Down NOTCH4, NOTCH 1, CCND1, AXL, WIP1
C-MYC, FRA1, CDK4, CDK6, SIRT1, E2F3
Cell Cycle control, invasion and metastasis, EMT, self-renewal and EMT, diagnostic biomarker, radiotherapy sensitive Bertoli et al. 2015 [3], Zhang et al. 2014 [60],
Schwarzenbacher et al. 2013 [61]
Kaboli et al. 2015 [58], Fu et al. 2011 [62]
O′ Day et al. 2010 [2]
125a-5p Cell line, Tissue Down HDAC4, HDAC5, HER3, HUR Inhibit cell proliferation and differentiation, induce apoptosis, Docetaxel sensitive, diagnostic biomarker Hsieh et al. 2015 [69], Bertoli et al. 2015 [3], Kaboli et al. 2015 [58], Zhang et al. 2014 [60]
125b Cell line, Tissue Down HER2, EST1, E2F3, EPO, EPOR, ENPEP, CK2-α, CCNJ, MEGF9, ERBB2, HUR, BAK Inhibit cell proliferation and differentiation, diagnostic biomarker, FEC chemotherapy resistant, Taxol resistant, Trastuzumab sensitive. Kurozumi et al. 2016 [57], Bertoli et al., 2015 [3],
Schooneveld et al. 2015 [36], Zhang et al. 2014 [60], Feliciano et al. 2013 [70], Wang et al. 2012 [71]
126 BC and TNBC cell line, Tissue Down IGFBP2, PITPNC1, MERTK, VEGF, IRS-1, PIK3R2 Cell cycle progression from G1/G0 to S, reduces metastasis and angiogenesis, diagnostic biomarker Kurozumi et al. 2016 [57], Bertoli et al. 2015 [3],
Zhang et al.2014 [60], Fu et al. 2011 [62]
128 Cell line and BCSCs Down BMI-1, ABCC5 Regulate cell cycle, inhibit tumor growth and angiogenesis, Doxorubicin sensitive Bertoli et al. 2015 [3], Kaboli et al. 2015 [58],
Schwarzenbacher et al. 2013 [61]
143 Serum Down HER3 Inhibit cell invasion and metastasis, diagnostic biomarker Schooneveld et al. 2015 [36], Kaboli et al. 2015 [58], Kodahl et al. 2014 [65]
145 Serum/Plasma/Tissue, Cell line Down EGF, C-MYC, VEGF, N-CADHERIN, HIF-2α, MUCIN1, HER3, IRS1, RTKN Inhibit cell invasion and metastasis, diagnostic biomarker Bertoli et al. 2015 [3], Schooneveld et al. 2015 [36], Zhang et al. 2014 [60], Kodahl et al. 2014 [65]
Fu et al. 2011 [62]
146 BC and TNBC cell line, Tissue Down BRCA1, NFκB, TRAF6, IRAK1, ROCK1, CXCR4, EGFR Proliferation, antiapoptotic, diagnostic biomarker Bertoli et al. 2015 [3], Shafi et al. 2014 [32]
146a BC and TNBC cell line, Tissue Down ICAM1, VHRF1, NF-Κb, EGFR Antimetastasis, symmetric and asymmetric division of CSCs Kurozumi et al. 2016 [57], Bertoli et al. 2015 [3], Kaboli et al. 2015 [58]
146b BC and TNBC cell line, Tissue Down ICAM1, VHRF1, NF-κB, STAT3, EGFR Anti-metastasis Kurozumi et al. 2016 [57], Schooneveld et al. 2015 [36], Kaboli et al. 2015 [58]
155 Serum, Heterogenous BC, Tissue Up CXCR4, FOXO3, TRF1, SHIP, TP53INPI, RHOA, SOCS1 Cell growth, proliferation, metastasis, telomere synthesis, TGF- β Signaling, diagnostic and prognostic biomarker, Taxane response Bertoli et al. 2015 [3], Schooneveld et al. 2015 [36],
Kodahl et al.2014 [65], Zhang et al. 2014 [60], Kaboli et al. 2015 [58], Fu et al. 2011 [62], O′ Day et al. 2010 [2]
181 Cell line and BCSCs, Serum Up ATM Regulate in vitro mammosphere formation, anti-apoptotic Bertoli et al. 2015 [3], Schwarzenbacher et al. 2013 [61], Kaboli et al. 2015 [58]
181b Tissue, Blood, Cell line Up SMAD3, BIM, CDK8 Promotes cell proliferation, migration and metastasis, associated with the resistance to Doxorubicin, diagnostic biomarker Zheng et al. 2015 [72], Kaboli et al. 2015 [58]
182 Cell line and tissue Up BRCA1, FOXO1 Proliferation, antiapoptotic, Tamoxifen response Kurozumi et al. 2016 [57], Bertoli et al. 2015 [3]
Kaboli et al. 2015 [58], Zhang et al. 2014 [60]
194 Tissue Up TLN2, CDH2, RAC1, THBS1, ITGA9 Antimetastastic, inhibit cell migration, enhance chemosensitivity, associate with trastuzumab (Herceptin) response, diagnostic biomarker. Bertoli et al., 2015 [3], Kaboli et al. 2015 [58], Calura et al. 2014 [73], Le et al. 2012 [74]
199b-5p Tissue, Cell line Down HER2 Regulate proliferation, invasion and metastasis, prognostic biomarker Fang et al. 2016 & 2013 [75, 76]
200 Tissue and Cell line Down BMI-1, SUZ12, ZEB1, ZEB2, PLCG1, TGFβ2, FAP-1, SNAI-1, SNAI-2, CTNNB1 Reduces tumor growth, anti-metastatic, stemness and EMT. Bertoli et al. 2015 [3], Kaboli et al. 2015 [58],
Shafi et al. 2014 [32], Hilmarsdottir et al. 2014 [77], Schwarzenbacher et al. 2013 [61], O′ Day et al. 2010 [2]
200a Tissue and Cell line Down SLUG, BMI1, ZEB1, ZEB2, EPHA2 Reduces tumor growth, anti-metastatic Tsouko et al. 2015 [78], Bertoli et al. 2015 [3], Kaboli et al. 2015 [58]
200b Tissue and Cell line Down SP1, RAB21, RAB23, RAB18, RAB3B Control cell proliferation and apoptosis, Prognostic biomarker Yao et al. 2015 [79], Ye et al. 2014 [80]
200c Tissue and cell line Down BMI1, ZEB1, ZEB2, FHOD1, PPM1F Reduces tumor growth, antimetastatic, inhibit clonogenicity of BCSCs, induce differentiation, sensitize breast cancer cells to doxorubicin, therapeutic biomarker Bertoli et al. 2015 [3], Kaboli et al. 2015 [58],
Zhang et al. 2014 [60], Jurmeister et al. 2012 [81], Fu et al. 2011 [62], Shimono et al. 2009 [82]
204 Tissue and cell line Down JAK2, ZEB2, FOXA1, BDNF, IL-11, PDEF, SIX1, SAM68 Inhibit cell growth, invasion and metastasis, induce cell apoptosis, suppress BCSCs, diagnostic and prognostic biomarker, Tamoxifen response Shen et al. 2017 [83], Li et al. 2016 [84], Flores-Pérez et al. 2016 [85], Bertoli et al. 2015 [3]
205 Ductal BC,BC and TNBC cell line Down HER3, E2F, P53, ZEB-1, HMGB3, VEGF-A, BRBB3 Inhibit proliferation, invasion and EMT, prognostic biomarker Bertoli et al. 2015 [3], Schooneveld et al. 2015 [36],
Takahashi et al. 2015 [59], Zhang et al.2014 [60], Fu et al. 2011 [62]
206 BC and TNBC cell line Down ERα, CCND2, ESR1, NOTCH3, SRC-1, SRC-3, GATA-3, ERα, Cx43 Reduces migration, invasion and anti-metastatic Bertoli et al. 2015 [3], Schooneveld et al. 2015 [36],
Kaboli et al. 2015 [58], Shafi et al. 2014 [32], Zhang et al. 2014 [60], Fu et al. 2011 [62], O′ Day et al. 2010 [2]
210 IDC, Cell line, Tissue, Plasma Up E2F3, NPTX1, RAD52, ACVR1B, MNT, CASP8AP2, FGFRL1, HOXA-1, HOXA-9 Prognostic and diagnostic biomarker, Herceptin resistance Bertoli et al. 2015 [3], Schooneveld et al. 2015 [36], Devlin et al. 2011 [86], Huang et al. 2010 [87]
216b Tissue and cell line Down SDCBP, P2X7 Suppress breast cancer growth and metastasis, proapoptoic, therapeutic biomarker Jana et al. 2016 [88], Kaboli et al. 2015 [58], Zheng et al. 2014 [60]
222 Serum, Tissue Up ABCG2, MMP1, SOD2, TIMP3, GNAI3 Inhibit migration and invasion, enhance breast cancer cells to cisplatin responsiveness, diagnostic and prognostic biomarker Bertoli et al. 2015 [3], Schooneveld et al. 2015 [36], Zhao et al. 2015 [89], Kodahl et al. 2014 [65]
221/222 Cell line Up ERα, P27kip1, KIT, P57, PTEN Tamoxifen resistant luminal type breast cancer and Fulvestrant resistant Bertoli et al. 2015 [3], Takahashi et al. 2015 [59]
Piva et al. 2013 [30], Fu et al. 2011 [62]
224 Tissue and Cell line Up CXCR4, CDC42, RKIP, FZD5, FZD4, Inhibited cell proliferation and migration Liu et al. 2014 [90], Zhang et al.2014 [60]
335 Cell line, Tissue Down SOX4, SPL, BCL-W, SOX4, TNC, PTPRN2, MERTK, RSP1, IGF1, ID4, ERα Suppress metastasis and migration, proapoptotic, diagnostic and prognostic biomarkers Bertoli et al. 2015 [3], Schooneveld et al. 2015 [36]
Kaboli et al. 2015 [58], Shafi et al. 2014 [32], Zhang et al. 2014 [60]
339-5p Tissue Down BCL6 Proapoptotic, Tamoxifen response Bertoli et al. 2015 [3], Kaboli et al. 2015 [58]
342-5p Heterogenous BC, Tissue Down EGRF, HER2, AKT, PKC, ESR1, ERN2, PELP1, SRC Regulate cell cycle, antiproliferative, diagnostic and prognostic biomarker, regulate Tamoxifen response Bertoli et al. 2015 [3], Schooneveld et al. 2015 [36]
Kaboli et al. 2015 [58], Leivonen et al. 2014 [91], Romero-Cordoba et al. 2012 [92]
373 Cell line Up CD44 Cell migration, invasion and metastasis Bertoli et al. 2015 [3], Schooneveld et al. 2015 [36], Shafi et al. 2014 [32], Fu et al. 2011 [62]
429 Cell line, Tissue Down ZEB1, ZEB2, CRKL, TUBB2A, TGF-β, XIAP Anti-proliferative and anti-metastatic, member of miR-200 family Takahashi et al. 2015 [59], Ye et al. 2015 [93],
Kaboli et al. 2015 [58], Wang et al. 2015 [94]
491-5p Cell line, Tissue Down EGRF, HER2, NNAT, JMJD2B Antiproliferative, antimetastatic especially estrogen stimulated breast cancer cells Hui et al. 2015 [95], Kaboli et al. 2015 [58]
495 Cell line, BCSCs Up REDDI, ECAD Increased tumor formation, downregulation of E-cadherin, maintaining a stem-cell line phenotype Kaboli et al. 2015 [58], Schwarzenbacher et al. 2013 [61]
520c Cell line, Tissue Up CD44 Cell migration, invasion and metastasis, Tamoxifen response Bertoli et al. 2015 [3], Kaboli et al. 2015 [58]
708 Tissue, Cell line Down NNAT Anti-proliferative and anti-metastatic Kurozumi et al. 2016 [57], Kaboli et al. 2015 [58], Ryu et al. 2013 [96]